BPC-157: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published preclinical research on BPC-157, including proposed mechanisms, study findings, purity standards for research use, and sourcing considerations for Canadian researchers.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. Its sequence is derived from a portion of human gastric juice protein, though the compound itself does not occur naturally in this exact form. It was first isolated and characterized by researchers at the University of Zagreb in the 1990s and has since been the subject of numerous preclinical studies.
All published research on BPC-157 to date has been conducted in rodent models. No peer-reviewed human clinical trials have been completed or published as of this writing. Researchers and institutions working with BPC-157 should source material verified by independent HPLC purity analysis and confirmed by mass spectrometry for identity — the two standards most relevant to research-grade procurement.
Proposed Mechanisms of Action
Several mechanisms have been proposed and studied in preclinical models. The following represent the most consistently reported pathways across the published literature:
Nitric Oxide (NO) System Modulation
Multiple studies have documented BPC-157's interaction with the nitric oxide system. Preclinical data suggests involvement in both eNOS and nNOS pathways, with proposed downstream effects on vascular tone and tissue perfusion in rodent models.
Growth Factor Upregulation
Rodent studies have observed associations between BPC-157 administration and upregulation of growth hormone receptor expression, as well as VEGF-related angiogenic signaling. These pathways are thought to contribute to the tissue repair endpoints observed in tendon and ligament studies.
Gastric Cytoprotection
BPC-157 was originally studied in the context of gastrointestinal mucosal protection. Research by Sikiric et al. documents consistent findings across ulcer, fistula, and inflammatory bowel models in rodents, with proposed mechanisms involving prostaglandin and mucus layer interactions.
Dopaminergic and Serotonergic Interaction
A subset of studies has examined BPC-157's effects on dopamine and serotonin system endpoints in rodent behavioral models. Researchers have documented modulation of receptor sensitivity in relevant brain regions, though the precise mechanism remains an active area of preclinical investigation.
Selected Published Research
The following is a selection of peer-reviewed studies available in PubMed. All studies listed are preclinical (rodent model) research. This is not a comprehensive literature review.
Sikiric P, et al. — Frontiers in Pharmacology, 2018
Reviews preclinical evidence on BPC-157 across multiple wound and tissue repair models in rodents, including tendon, ligament, and gastrointestinal contexts.
Sikiric P, et al. — Journal of Clinical & Experimental Pharmacology, 2014
Rodent model study examining BPC-157 interaction with dopaminergic and serotonergic systems in relation to behavioral endpoints.
Sikiric P, et al. — Current Neuropharmacology, 2021
Preclinical review of BPC-157 studies examining CNS-related pathways, focusing on nitric oxide system involvement and neurological endpoints.
Chang CH, et al. — Journal of Applied Physiology, 2011
Rodent study examining the effect of BPC-157 administration on Achilles tendon repair metrics including breaking strength and histological markers.
Purity Standards for Research Use
When procuring BPC-157 for laboratory research, purity and identity verification are the two most critical quality parameters. Here is what each test confirms and why it matters:
HPLC Purity Analysis
High-performance liquid chromatography separates the compound from impurities and degradation products. Research-grade BPC-157 should meet ≥99%+ purity by HPLC. This is the standard used in published preclinical studies and the baseline expectation for any reputable supplier.
Mass Spectrometry (Identity)
MS confirms the molecular weight and fragmentation pattern of the compound, verifying it is what it claims to be — not a structurally similar substitute or mislabeled product. Identity confirmation by MS is distinct from purity and both are required for research-grade procurement.
Endotoxin Testing
Bacterial endotoxin testing (LAL method) is relevant for in vivo research use. Endotoxin contamination can confound experimental results in animal models, making this a critical parameter for researchers conducting in vivo studies.
Certificate of Analysis (COA)
A batch-specific COA documents the HPLC result, MS data, endotoxin level, appearance, and storage conditions for that specific lot. Institutions require COAs for procurement records. The COA should be batch-specific — not a generic document reused across lots.
Sourcing BPC-157 in Canada
Researchers in Canada have historically relied on US-based suppliers, which introduces shipping delays, customs exposure, and inconsistent documentation standards. A domestic Canadian source with full third-party testing eliminates these variables.
ACCUTIDE Research Supply provides BPC-157 tested to ≥99%+ HPLC purity with batch-specific COA documentation. All material is lyophilized for stability and ships Canada-wide with appropriate cold-chain packaging.
BPC-157 — Canadian Research Supply
HPLC tested · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Bpc-157 in preclinical research literature.
Often co-investigated for musculoskeletal recovery — the classic BB-20 pairing in preclinical research.
Copper-binding tripeptide studied alongside BPC-157 for collagen remodeling and wound repair.
Anti-inflammatory melanocortin-derived peptide frequently paired in mucosal and gut repair research.
Research Use Only Disclaimer: All information on this page is provided for scientific research and educational purposes only. BPC-157 supplied by ACCUTIDE Research Supply is strictly for laboratory and research use (RUO). It is not intended for human or animal consumption, therapeutic use, or any application outside of controlled research settings. All published studies referenced are preclinical rodent model research. No human clinical trials data exists for BPC-157 as of this publication.